151 related articles for article (PubMed ID: 1707083)
41. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by luteinizing hormone-releasing hormone analogs in the treatment of metastatic carcinoma of the prostate.
Boccon-Gibod L; Laudat MH; Dugue MA; Steg A
Eur Urol; 1986; 12(6):400-2. PubMed ID: 2949980
[TBL] [Abstract][Full Text] [Related]
42. [Fatal subfulminant hepatitis caused by cyproterone acetate].
Antoni M; Bourlière M; Toullec J; Maillot A; Botta-Fridlund D; Gauthier A
Gastroenterol Clin Biol; 1991; 15(10):772-3. PubMed ID: 1840042
[No Abstract] [Full Text] [Related]
43. Gestagens in the management of prostatic carcinoma.
Szendröi Z
Int Urol Nephrol; 1984; 16(4):327-35. PubMed ID: 6100181
[TBL] [Abstract][Full Text] [Related]
44. Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acetate.
Schroeder FH; Lock TM; Chadha DR; Debruyne FM; Karthaus HF; de Jong FH; Klijn JG; Matroos AW; de Voogt HJ
J Urol; 1987 May; 137(5):912-8. PubMed ID: 2952810
[TBL] [Abstract][Full Text] [Related]
45. Striking regression of advanced prostatic carcinoma induced by cyproterone acetate (Androcur). A case report.
Varenhorst E; Björnlert U; Carlström K
Scand J Urol Nephrol; 1981; 15(2):157-9. PubMed ID: 7330610
[TBL] [Abstract][Full Text] [Related]
46. Cyproterone acetate, testosterone, LH, FSH, and prolactin levels in plasma after intramuscular application of cyproterone acetate in patients with prostatic cancer.
Rost A; Schmidt-Gollwitzer M; Hantelmann W; Brosig W
Prostate; 1981; 2(3):315-22. PubMed ID: 6458025
[TBL] [Abstract][Full Text] [Related]
47. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.
Goldenberg SL; Bruchovsky N; Rennie PS; Coppin CM
J Urol; 1988 Dec; 140(6):1460-5. PubMed ID: 2973529
[TBL] [Abstract][Full Text] [Related]
48. Endocrine effects of cyproterone acetate in patients with prostatic cancer.
Isurugi K; Fukutani K; Ishida H; Hosoi Y
J Urol; 1980 Feb; 123(2):180-3. PubMed ID: 7354512
[TBL] [Abstract][Full Text] [Related]
49. [Hepatitis after treatment with cyproterone acetate. Apropos of a case].
Dore B; Orget J; Irani J; Aubert J
J Urol (Paris); 1990; 96(3):169-71. PubMed ID: 2145371
[TBL] [Abstract][Full Text] [Related]
50. Cyproterone acetate monotherapy in advanced prostatic carcinoma.
Kayigil O; Atahan O; Metin A
Int Urol Nephrol; 1997; 29(2):213-20. PubMed ID: 9241550
[TBL] [Abstract][Full Text] [Related]
51. Orchiectomy combined with cyproterone acetate or prednisone in the treatment of advanced prostatic carcinoma. A randomized clinical and endocrine study.
Sander S; Nissen-Meyer R; Aakvaag A
Scand J Urol Nephrol; 1982; 16(3):193-7. PubMed ID: 6219455
[TBL] [Abstract][Full Text] [Related]
52. The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer.
de Voogt HJ
Prostate Suppl; 1992; 4():91-5. PubMed ID: 1533452
[TBL] [Abstract][Full Text] [Related]
53. Adenocarcinomas of the prostate induced by N-nitroso-N-methylurea in rats pretreated with cyproterone acetate and testosterone.
Bosland MC; Prinsen MK; Kroes R
Cancer Lett; 1983 Feb; 18(1):69-78. PubMed ID: 6218869
[TBL] [Abstract][Full Text] [Related]
54. Investigation on serum neurone-specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay.
Tarle M; Radoś N
Prostate; 1991; 19(1):23-33. PubMed ID: 1715080
[TBL] [Abstract][Full Text] [Related]
55. Treatment of symptomatic metastatic prostatic cancer with cyproterone acetate versus orchiectomy: a prospective randomized trial.
Ostri P; Bonnesen T; Nilsson T; Frimodt-Møller C
Urol Int; 1991; 46(2):167-71. PubMed ID: 1711250
[TBL] [Abstract][Full Text] [Related]
56. Effects of oestrogens, orchidectomy and cyproterone acetate on salt and water metabolism in carcinoma of the prostate.
Varenhorst E; Karlberg BE; Wallentin L; Wranne B
Eur Urol; 1981; 7(4):231-6. PubMed ID: 6453004
[TBL] [Abstract][Full Text] [Related]
57. [Cyproterone acetate. Its value in the treatment of prostatic cancer. Apropos of 45 cases].
Tobelem G; Arvis G
Therapie; 1988 May; 43(3):179-82. PubMed ID: 2971278
[No Abstract] [Full Text] [Related]
58. Pituitary adrenal and gonadal endocrine suppression for the primary treatment of prostate cancer.
Williams G; Asopa R; Abel PD; Smith C
Br J Urol; 1990 May; 65(5):504-8. PubMed ID: 2141289
[TBL] [Abstract][Full Text] [Related]
59. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.
Pavone-Macaluso M; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R
J Urol; 1986 Sep; 136(3):624-31. PubMed ID: 2942707
[TBL] [Abstract][Full Text] [Related]
60. Antiandrogen withdrawal syndrome with cyproterone acetate.
Sella A; Flex D; Sulkes A; Baniel J
Urology; 1998 Dec; 52(6):1091-3. PubMed ID: 9836560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
